Amgen and Pfizer appoint new Science executives
The new executive recruits at Amgen and Pfizer will support advancement in therapeutic areas including oncology and rare disease.
List view / Grid view
The new executive recruits at Amgen and Pfizer will support advancement in therapeutic areas including oncology and rare disease.
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
Following the appointment, Thomas Hudson, AbbVie’s current Senior Vice President, Chief Scientific Officer, Global Research, will retire.
The new Executive Vice President (EVP) has over “25 years of experience and a proven track record of leading strategic quality initiatives”, Eli Lilly and Company shared.
The new Executive Vice President of Teva Global Operations will bring “significant experience at every stage of the manufacturing and supply process” to his new role, the company asserted.
The incoming CEO of the contract development and manufacturing organisation (CDMO) Lonza will transition into his new role over Summer 2024.
An ex-Biogen executive has been appointed as CDMO FUJIFILM Diosynth Biotechnologies’ new Chief Quality Officer.
Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.
CEOs from Pfizer, Roche and Daiichi Sankyo will join the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)’s new CEO leadership team.
Bristol Myers Squibb’s leadership team is set to reshuffle, with Christopher Boerner becoming it’s new CEO in late 2023.
Two Big Pharma companies have announced management changes in 2023: Astellas will have a new President and CEO and Bayer AG will be led by a new CEO.
Dr Eric Hughes will join Teva as Executive Vice President, Global R&D and Chief Medical Officer in August, assuming the role from Dr Hafrun Fridriksdottir, who has been with Teva for 25 years.
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Dr Roy Baynes, Merck’s head of Global Clinical Development (GCD) and Chief Medical Officer, will retire in July.